Thrombocytopenia
Drug research and approvals for thrombocytopenia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 185 studies of thrombocytopenia are recruiting on ClinicalTrials.gov, Health Canada has authorized 11 drug trials for it since 2013, FDA has 12 approved and 28 open orphan designations naming it, and the EU has 7 authorised medicines for it.
- Recruiting worldwide: 185
- Trials authorized in Canada: 11
- FDA orphan approvals: 12
- EU medicines: 7
Recruiting Now
Newest start dates first, of 185 recruiting on ClinicalTrials.gov ↗- TGD001 Treatment in Thrombotic MicroangiopathiesNCT07459114 · Phase 1 / Phase 2 · TargED Biopharmaceuticals B.V. · starts Oct 25, 2026
- Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With CytopeniasNCT07447817 · Phase 2 · John Mascarenhas · starts Oct 23, 2026
- rhTPO for Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Procedures.NCT07911800 · Phase 3 · MIBIO PTE. LTD. · starts Oct 20, 2026
- A Study to Learn More About the Treatment of People With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Who…NCT07429942 · Not reported · Takeda · starts Sep 24, 2026
- Role of Viscoelastometric Testing in the Development and Validation of a Clinical-biological Score for Predicting…NCT07653672 · Not reported · Centre Hospitalier Annecy Genevois · starts Sep 18, 2026
- The Role of interferOn and Complement in SecondAry thRombotic micrioangiOpathyNCT07705789 · Not applicable · Sofie Dhaese · starts Sep 15, 2026
- Safety and Efficacy of Iptacopan in Patients With High-Risk Transplantation-Associated Thrombotic MicroangiopathyNCT07347990 · Not applicable · First Affiliated Hospital of Zhejiang University · starts Aug 25, 2026
- A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary…NCT07700238 · Phase 3 · Amgen · starts Aug 21, 2026
- A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC…NCT07421167 · Phase 2 · Novartis Pharmaceuticals · starts Aug 4, 2026
- Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune DiseaseNCT07549698 · Phase 1 / Phase 2 · CRISPR Therapeutics AG · starts Jul 17, 2026
Trials Authorized in Canada
The 10 newest of 11; search them all in Canada trials| May 26, 2026 | A phase 3, randomized, multicenter, open-label study to evaluate the efficacy and safety of romiplostim plus predniso(lo)ne vs. predniso(lo)ne alone for the…NPLATE (ROMIPLOSTIM) | Amgen | Pending |
| Apr 21, 2026 | A randomized, multi-center, double-blind, phase . study evaluating the efficacy and safety of hetrombopag olamine tablets vs placebo in patients with…RAFUTROMBOPAG (HETROMBOPAG, SHR8735) | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pending |
| Oct 18, 2024 | Double-blind, randomized, placebo-controlled study evaluating the safety and efficacy of nipocalimab in reducing the risk of fetal and neonatal alloimmune…NIPOCALIMAB | Johnson & Johnson | Pending |
| Nov 5, 2021 | An interventional phase 2, open-label, one-arm, multicenter study to evaluate safety and efficacy of pf-06835375 in adult participants with moderate to severe…PF-06835375 | Pfizer | Closed |
| Dec 1, 2020 | A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study with an open-label extension to evaluate the efficacy and safety of…RILZABRUTINIB (PRN1008) | PRINCIPIA BIOPHARMA INC | Ongoing |
| Jul 9, 2019 | An open-label, randomised, active controlled, multi-centre phase 3 study to evaluate the safety and efficacy of danaparoid vs argatroban in treatment of…ORGARAN (DANAPAROID SODIUM) | Aspen Global Inc | Ongoing |
| May 6, 2015 | A phase 3 randomised, double-blind, placebo-controlled study to assess the safety and efficacy of s-888711 (lusutrombopag) for the treatment of…LUSUTROMBOPAG (S-888711) | Shionogi | Closed |
| Nov 4, 2014 | A single arm, open-label, long-term efficacy and safety study of romiplostim in thrombocytopenic pediatric subjects with immune thrombocytopenia (itp)NPLATE (ROMIPLOSTIM) | Amgen | Ongoing |
| Oct 10, 2014 | Open label, adaptive design, ascending, multiple-dose study to evaluate safety and efficacy of bms-986004 (anti-cd40l dab) in adult subjects with primary…BMS 986004 (ANTI-CD40L DOMAIN ANTIBODY) | Bristol-Myers Squibb | Ongoing |
| May 9, 2014 | A randomized controlled phase 3 study of oral pacritinib versus best available therapy in patients with thrombocytopenia and primary myelofibrosis,…PACRITINIB (SB1518) | CTI BIOPHARMA CORP | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 40| Aug 29, 2025 | Wayrilztreatment of adult patients with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous… | Genzyme Corporation (A Sanofi Company) | Approved |
| Jul 24, 2025 | Doptelettreatment of thrombocytopenia in pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia who have had an… | Sobi, Inc. | Approved |
| Oct 17, 2019 | NplateNplate is indicated for the treatment of thrombocytopenia in adult patients with immune thrombocytopenia (ITP) who have had an insufficient… | Amgen, Inc. | Approved |
| Jun 26, 2019 | avatrombopag maleateDOPTELET is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an… | Sobi, Inc. | Approved |
| Dec 14, 2018 | NplateNplate is indicated for the treatment of thrombocytopenia in pediatric patients 1 year of age and older with ITP for at least 6 months who… | Amgen, Inc. | Approved |
| Apr 17, 2018 | fostamatinib disodium hexahydrateTAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an… | Rigel Pharmaceuticals, Inc. | Approved |
| Mar 8, 2013 | GammaplexIdiopathic thrombocytopenic purpura | Bio Products Laboratory | Approved |
| Nov 20, 2008 | PromactaTreatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura who have had an insufficient response… | Novartis Pharmaceuticals Corp. | Approved |
| Aug 22, 2008 | NplateTreatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient… | Amgen, Inc. | Approved |
| May 19, 2004 | VidazaTreatment of patients with the following myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts… | Celgene Corporation | Approved |
| Mar 6, 1998 | RefludenFor anticoagulation in patients with heparin-induced thrombocytopenia and associated thromboembolic disease in order to prevent further… | Hoechst Marion Roussel | Approved |
| Nov 25, 1997 | NeumegaPrevention of severe chemotherapy-induced thrombocytopenia. | Genetics Institute, Inc. | Approved |
| Oct 24, 2026 | sovleplenib acetatetreatment of primary immune thrombocytopenia | HUTCHMED Limited | Designated |
| Aug 22, 2026 | pirtobrutinibtreatment of primary immune thrombocytopenia | Eli Lilly and Company | Designated |
| Jan 13, 2026 | a universal platelet-promoting megakaryocyte derived from…treatment of post-hematopoietic stem cell transplantation thrombocytopenia | HemaNiche Biotech Co., Ltd | Designated |
Medicines Authorised in the EU
Newest first| Dec 22, 2025 | Wayrilzrilzabrutinib · orphan | Sanofi B.V. | EMA ↗ |
| Mar 28, 2025 | Eltrombopag Accordeltrombopag · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Dec 12, 2024 | Eltrombopag Viatriseltrombopag · generic | Viatris Limited | EMA ↗ |
| Jan 9, 2020 | Tavlessefostamatinib | Instituto Grifols S.A. | EMA ↗ |
| Jun 20, 2019 | Dopteletavatrombopag | Swedish Orphan Biovitrum AB (publ) | EMA ↗ |
| Mar 11, 2010 | Revoladeeltrombopag | Novartis Europharm Limited | EMA ↗ |
| Feb 4, 2009 | Nplateromiplostim | Amgen Europe B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA